There is significant value still left in the suite of drugs that...

  1. 2,524 Posts.
    lightbulb Created with Sketch. 142
    There is significant value still left in the suite of drugs that Mesoblast trialled and that missed endpoints, potentially billions in the hands of the right major global pharmaceutical company. As for the share price, I'd rather be in Mesoblast today at its current share price and awaiting potential offers or take over offers, or re-occurring revenues from the drug suite. We have all the answers and the pieces of the puzzle, it just needs to be carefully put together now.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$2.41
Change
0.620(34.6%)
Mkt cap ! $3.084B
Open High Low Value Volume
$1.90 $2.48 $1.90 $58.82M 25.68M

Buyers (Bids)

No. Vol. Price($)
3 100915 $2.40
 

Sellers (Offers)

Price($) Vol. No.
$2.41 99 1
View Market Depth
Last trade - 16.12pm 18/07/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.